Journal article

Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab

MJ Bishton, MF Leahy, RJ Hicks, JH Turner, AD McQuillan, JF Seymour

Annals of Oncology | OXFORD UNIV PRESS | Published : 2008

DOI: 10.1093/annonc/mdn172

Citation metrics

11Web of Science
12Scopus

Keywords

Dose-Response Relationship, Drug
Science & Technology
Cohort Studies
Iodine I-131 Tositumomab
Rituximab
Life Sciences & Biomedicine
Antigens, Cd20
Kaplan-Meier Estimate
Male
Therapy
Radioimmunotherapy
Lymphoma
Adult
Middle Aged
Probability
Infusions, Intravenous
Retrospective Studies
Follicular Lymphoma
Combination
Female
Antibodies, Monoclonal
Follow-Up Studies
Antibodies, Monoclonal, Murine-Derived
Low-Grade
Survival Analysis
Risk Assessment
Oncology
Aged, 80 and Over
Drug Administration Schedule
Repeat
Iodine Radioisotopes
Humans
Treatment Outcome
Ibritumomab Tiuxetan
Lymphoma, B-Cell
Retreatment
Cyclophosphamide
Neoplasm Recurrence, Local